邓成珊扶正解毒治疗骨髓增生异常综合征经验 骨髓异常增生综合征（myelodysplastic syndromes，MDS）是一组源于造血干细胞的获得性克隆性疾病，根据血象和骨髓象可分为难治性贫血、难治性贫血伴原始细胞增多、难治性贫血伴原...
基于100个网页-相关网页
骨髓增生异常综合征 myelodysplastic syndrome ; MDS ; RCMD ; myelodysplastic syndromes MDS
测骨髓增生异常综合征 myelodysplastiesyndrome
例骨髓增生异常综合征 myelodgsplastic syndrome
的骨髓增生异常综合征 myelodyplastic syndrome
危骨髓增生异常综合征 myelodysplastic syndrome
在骨髓增生异常综合征 myelodysplastic syndrome
其他骨髓增生异常综合征 Other myelodysplastic syndromes
未特指的骨髓增生异常综合征 Myelodysplastic syndrome, unspecified
比较24例骨髓异常增生综合征难治性贫血与59例慢性再生障碍性贫血的临床特点和实验室资料。
Methods The clinical characteristics and experimental data of 24 patients with MDS-RA and 59 cases with CAA were analysed.
他的团队探讨骨髓增生异常综合征的患者血红蛋白合成异常的情况。
His team investigated the state of abnormal composition of hemoprotein in myelodysplastic syndrome.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病 骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
应用推荐